travellinglight
- Anavex Life Sciences (AVXL) has formally asked the European Medicines Agency to re-examine its opinion made earlier in December that the company’s treatment for early-stage Alzheimer’s, blarcamesine, be rejected.
- A new evaluation of the company’s marketing authorization application will take
